Back to Top Skip to main content

WRNMMC expands innovation and opens new, permanent drive-thru pharmacy

Military pharmacist, wearing a mask, looking at bags of prescriptions Army Sgt. Tyson Boothe filling a patient’s prescription at Walter Reed National Military Medical Center’s new Prescription Drive-Thru Pick-up located in in the parking lot of building 85T near Gate 1 (North gate). (Photo by Sean Patten, WRNMMC.)

Recommended Content:

Research and Innovation | Combat Support | Public Health | Coronavirus | Health Literacy Month 2020

On Sept. 22, Walter Reed National Military Medical Center (WRNMMC) held a ribbon cutting ceremony celebrating the grand opening of a new Prescription Drive-Thru Pick-Up near Naval Support Activity Bethesda’s Gate 1 (North gate).

During the onset of the COVID-19 pandemic, pharmacy team at WRNMMC quickly made adjustments to pharmacy operations in order to support social distancing and patient convenience.

In this effort, a curbside pharmacy-pick-up was implemented at the America Building (Bldg. 19) pharmacy and allowed for prescription pick-up without having to enter a building. Taking note of the prescription pick-up’s popularity, the WRNMMC pharmacy team set out to improve on this idea.

The new Prescription Drive-Thru Pick-up will operate similarly as the curbside pharmacy pick-up. The pharmacy team believes the new location and building will enhance their patient’s experience.

“This new prescription drive-thru pick-up will be a better environment for staff; and a more convenient and satisfying experience for patients,” stated Navy Cmdr. Emily Zywicke, chief of WRNMMC Pharmacy Department. “The new Prescription Drive-Thru Pick-up requires the patient to activate their new or refill medication 24 hours in advance, by phone or via TRICARE Online. The patient may drive-thru the new pharmacy pick-up in the parking lot of building 85T and have their medications within minutes.”

At the ribbon cutting ceremony, hospital leadership celebrated the hard work the Pharmacy Team put into making the Prescription Drive-thru Pick-up a reality. WRNMMC Chief of Staff Army Col. Anthony Meador, and Director for Clinical Support Services Army Col. Kari McRae both made remarks in recognition of the pharmacy team’s efforts.

“The Pharmacy Team has demonstrated tremendous innovation,” said McRae. “They are not just a group of doers, they are also a group of thinkers,” she added.

You also may be interested in...

DHA-IPM 20-004: Department of Defense (DoD) Coronavirus Disease 2019 (COVID-19) Vaccination Program Implementation

Policy

This Defense Health Agency (DHA) Interim Procedures Memorandum (IPM), based on the authority of References (a) through (d), and in accordance with the guidance cited in References (e) through (aa), establishes the DHA’s procedures to implement instructions, assign responsibilities, and prescribe procedures for the COVID-19 Vaccination Program. This DHA-IPM applies to DHA, DHA Components (activities under the authority direction, and control of the DHA), Military Departments (MILDEP), and the United States Coast Guard (CG). This DHA-IPM cancels and replaces DHA-IPM 20-004, “Department of Defense (DoD) Coronavirus Disease 2019 (COVID-19) Vaccination Program Implementation,” December 13, 2020.

Supplemental Guidance for Providing DoD Coronavirus Disease 2019 Vaccines to DoD Contractor Employees and Select Foreign Nationals

Policy

This memorandum provides supplemental guidance on the provision of coronavirus disease 2019 (COVID-19) vaccines, in accordance with reference (a). The Defense Health Agency (DHA) is the lead coordinating DoD Component for executing this guidance, in coordination with the Military Departments and other DoD Components as appropriate.

HA Guidance for Coronavirus Disease 2019 (COVID-19) Laboratory Pre-Testing Questionnaire

Policy

This memorandum provides guidance for a COVID-19 laboratory pre-testing questionnaire that will be mandatory for all Active Duty Service members and encouraged for all other DoD beneficiaries treated at military medical treatment facilities.

Executive Order on Ensuring Access to United States Government COVID-19 Vaccines

Policy

This EO outlines who should receive priority access to COVID-19 vaccines developed in the United States or procured by the United States Government (“United States Government COVID-19 Vaccines”).

Coronavirus Disease 2019 Vaccine Guidance

Policy

This memorandum provides guidance on the provision of coronavirus disease 2019 (COVID-19) vaccines. The Defense Health Agency (DHA) is the lead coordinating DoD Component for executing this guidance, in coordination with the Military Departments and other DoD Components.

DHA-PI 6205.01: Medical Logistics Guidance for the DoD Coronavirus Disease 2019 (COVID-19) Vaccination Program

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (n), establishes the Defense Health Agency's (DHA's) procedures for ordering, receiving, and managing COVID-19 Vaccines inventory and ancillary kits.

DHA-AI 3020-01: Return to the Workplace Staffing Plan in the Coronavirus Disease 2019 Environment

Policy

This Defense Health Agency-Administrative Instruction (DHA-AI), based on the authority of References (a) through (b) and in accordance with the guidance of References (c) through (z3), establishes the Defense Health Agency's (DHA) plan to return to full operations and support the whole-of-government response, during the Coronavirus Disease 2019 (COVID-19) pandemic. This DHA-AI also provides a preventive plan to monitor and assess for the appearance of new cases and implement those processes that will prevent them from impacting the workforce. The processes describe herein are intended to offer an actionable plan for the workforce to re-enter DHA Administrative Offices. See Appendix 1 for a summary of the DHA Administrative Office Reopening Plan. The plan uses the Force Health Protection Guidance and Health Protection Conditions (HPCON), in accordance with Reference (d), to ensure protection for the workforce, including the most vulnerable-to-serious complications from the virus while enabling DHA Administrative Offices to continue its mission. See Appendix 2 for the conceptual HPCON framework.

  • Identification #: 3020-01
  • Date: 11/3/2020
  • Type: Administrative Instructions
  • Topics: Coronavirus

DHA AI 3020.01: Return to the Workplace Staffing Plan in the Coronavirus Disease 2019 (COVID-19) Environment

Policy

This Defense Health Agency-Administrative Instruction (DHA-AI), establishes the Defense Health Agency’s (DHA) plan to return to full operations and support the whole-of-government response, during the Coronavirus Disease 2019 (COVID-19) pandemic and in preparation for regression or resurgence in COVID-19 cases that could impact the workforce.

  • Identification #: DHA AI 3020.01
  • Date: 6/12/2020
  • Type: Administrative Instructions
  • Topics: Coronavirus

DHA-PI 3200.01: Research and Development (R&D) Enterprise Activity (EA)

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (p): a. Establishes the Defense Health Agency’s (DHA) procedures for the Deputy Assistant Director (DAD), R&D to manage and execute, on behalf of the Assistant Secretary of Defense for Health Affairs (ASD(HA)), the portion of the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation assigned to it (referred to as the “DHP Science and Technology (S&T) Program)”. The DHP S&T Program includes Budget Activities (BAs) 6.1-6.3 and 6.6. The ASD(HA) provides policy, direction, and guidance to inform planning, programming, budgeting, and execution of the DHP RDT&E appropriation in accordance with statute, regulation, and policy in Reference (a). The DAD-R&D, and Component Acquisition Executive (CAE) manage and execute DHP RDT&E Program funds aligned to them on behalf of the ASD(HA). The CAE is responsible for managing BAs 6.4, 6.5, and 6.7 funding, as well as Procurement and Operations and Maintenance funding required to support DHP-funded Acquisition Programs, regardless of acquisition activity. b. Supports the Director, DHA, in developing appropriate DHA management models to maximize efficiencies in the management and execution of DHP RDT&E-funded activities carried out by the Combatant Commands (CCMDs), Services, Uniformed Services University of the Health Sciences (USU), Defense Agencies, and other DoD Components, as applicable. c. Codifies processes to confirm DHP RDT&E funds are applied towards medical priorities and aligned to ASD(HA) policy, direction, and guidance to develop and deliver innovative medical products and solutions that increase the readiness of the DoD medical mission in accordance with Reference (a). d. Supports the following objectives of the R&D EA: (1) Increasing the quantity, quality, and pace of medical research through improved programmatic organization, processes, and oversight. (2) Ensuring DHP RDT&E funded efforts align to ASD(HA) published program guidance that provides resourcing guidance and translates national, departmental, and Service priorities into specific program objectives. (3) Verifying alignment of DHP RDT&E funds to medical priorities and to ASD(HA) policy, direction, and guidance to ensure the development and delivery of medical materiel and knowledge solutions. (4) Facilitating coordination with the CCMDs, Services, USU, Defense Agencies, and other DoD Components, as applicable, to ensure DHP RDT&E funded activities address joint medical capability gaps, and avoid unnecessary duplication.

Embedded Fragment Analyses

Policy

Clarification of the Requirement for Continuation of Semi-Annual Reporting of Results of Embedded Fragment Analyses

Influenza Surveillance Program

Policy

Sentinel Sites for the 2014-2015 Influenza Surveillance Program

Deployment Limiting Mental Disorders and Psychotrophic Medications

Policy

Policy memorandum about Deployment Limiting Mental Disorders and Psychotrophic Medications

Guidance on the Establishment of a Human Cell, Tissue, and Cellular and Tissue Based Products Program

Policy

This memorandum requests the Services resource a Human Cell, Tissue, and Cellular and Tissue Based Products (HCT/Ps) Program that complies with regulatory standards for management and oversight of HCT/Ps, according to the best fit for their Service.

Access to Medical Services Who were Exposed to Rabies in Combat Theater

Policy

U.S. Navy/U.S. Marine Corps COSC Policy Update

Policy
<< < 1 2 > >> 
Showing results 1 - 15 Page 1 of 2

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.